Laurus Labs to Invest Up to €9.8M in JV KRKA Pharma for New Facility
Laurus Labs will invest up to €9.8 million (approx. ₹87.4 crore) in its joint venture, KRKA Pharma. The co-venturer will invest €10.2 million (approx. ₹90.3 crore). Funds will be used for a new manufacturing facility. The investment is expected by FY27.
The investment is a significant capital expenditure for a new manufacturing facility, which could lead to future growth, but the immediate financial impact is spread over the next financial year.
The investment in a joint venture to establish a new manufacturing facility aligns with the company's strategic growth plans and long-term business objectives, indicating positive future development.
Laurus Labs Limited announced on April 30, 2026, that its Board of Directors approved an investment of up to EUR 9,800,000 (approximately ₹87.4 crore) in its joint venture, KRKA Pharma Private Limited.
The co-venturer, KRKA d.d., Novo mesto, Slovenia, will also invest approximately EUR 10,200,000 (approximately ₹90.3 crore) in KRKA. The existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs Limited will remain unchanged after this additional investment.
This strategic investment is intended to support KRKA Pharma's capital expenditure plan for establishing a new manufacturing facility. KRKA Pharma Private Limited was incorporated in April 2024 and is in the pharmaceutical industry. The company is currently rendering R&D services, with a turnover of INR 10.47 million (₹0.93 crore) in FY26. The investment, structured as a cash consideration through subscribing to equity shares, is expected to be completed during the financial year 2026-27.
The Board meeting commenced at 02:00 p.m. and concluded at 03:00 p.m. on April 30, 2026.
What to do with a filing like this
Laurus Labs Limited filed this with the NSE as a statutory disclosure, categorised under joint ventures. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laurus Labs Limited. Read the original for the full detail.